Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Company    BMY

BRISTOL-MYERS SQUIBB COMPANY (BMY)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
08/09/2018 08/10/2018 08/14/2018 08/15/2018 08/16/2018 Date
59.53(c) 59.31(c) 59.96(c) 60.26(c) 61.11(c) Last
3 998 528 3 535 516 5 212 832 5 214 561 7 285 527 Volume
-1.06% -0.37% +1.10% +0.50% +1.41% Change
More quotes
Financials (USD)
Sales 2018 22 250 M
EBIT 2018 5 813 M
Net income 2018 4 663 M
Finance 2018 188 M
Yield 2018 2,67%
Sales 2019 23 475 M
EBIT 2019 6 456 M
Net income 2019 5 942 M
Finance 2019 2 114 M
Yield 2019 2,75%
P/E ratio 2018 21,77
P/E ratio 2019 16,86
EV / Sales2018 4,41x
EV / Sales2019 4,10x
Capitalization 98 337 M
More Financials
Company
Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products.It includes chemically-synthesized drugs or small molecules and products produced from biological processes called biologics.The company was... 
Sector
Pharmaceuticals
Calendar
10/25Earnings Release
More about the company
Surperformance© ratings of Bristol-Myers Squibb Compa
Trading Rating : Investor Rating :
More Ratings
Latest news on BRISTOL-MYERS SQUIBB COMPA
01:00pBRISTOL MYERS SQUIBB : U.S. Food and Drug Administration Approves Opdivo® (nivol..
BU
08/16ELI LILLY AND : Researchers Submit Patent Application, "Gamma Secretase Modulato..
AQ
08/16BRISTOL MYERS SQUIBB : Scientists create atomic glue gun to build better nucleic..
AQ
08/16CLOVIS ONCOLOGY : Announces First Patient Enrolled in the Phase 3 ATHENA Trial
AQ
08/16BRISTOL MYERS SQUIBB : Patent Application Titled "Treatment Of Cancer Using A Co..
AQ
08/16EMWNEWS.COM : Medical News Reports on The Gift of a Normal Life College & Medica..
AQ
08/09BRISTOL MYERS SQUIBB : Determination That PROLIXIN (Fluphenazine Hydrochloride) ..
AQ
08/09CLOVIS ONCOLOGY : Announces First Patient Enrolled in the Phase 3 ATHENA Trial
AQ
08/08BRISTOL MYERS SQUIBB : Scientists Create Atomic Glue Gun to Build Better Nucleic..
AQ
08/07BRISTOL MYERS SQUIBB : Scripps Research, Bristol-Myers Squibb Scientists Create ..
AQ
More news
Sector news : Pharmaceuticals - NEC
11:52aNOVO NORDISK A/S : Invests in Diabetes Treatment With Deal That Could Exceed $80..
DJ
08:15aSHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
08/16TEVA PHARMACEUTICAL INDUSTRIES : Antares Pharma Shares Rise After FDA Approves F..
DJ
08/16GLAXOSMITHKLINE : to Close Skincare Factory in Ireland
DJ
08/16BASF : Bayer says can begin integration of Monsanto
RE
More sector news : Pharmaceuticals - NEC
MarketScreener Strategies on BRISTOL-MYERS SQUIBB COMPA 
BRISTOL-MYERS SQUIBB CO - 2016
Attractive price levels
BUY
More Strategies
Latest Tweets
01:10pBristol-Myers wins FDA okay for Opdivo as treatment for small-cell lung cance.. 
01:10pBristol-Myers wins FDA approval for Opdivo as treatment for small cell lung c.. 
01:09pBristol-Myers wins FDA approval for Opdivo as treatment for small cell lung c.. 
01:03pBristol-Myers says FDA has approved opdivo as treatment for small cell lung c.. 
01:01p$BMY FDA Approves Opdivo as the First New Medication in Nearly 20 Years for C.. 
More tweets
Qtime:259
News from SeekingAlpha
08/16Iovance updates on TIL collaborations 
08/11You Should Not Miss Bristol-Myers Squibb In 2018 
08/11STOCKS TO WATCH : Any Privacy For Tesla? 
08/10EAA Announces August 2018 Portfolio 
08/093 THINGS IN BIOTECH, AUGUST 9 : Clovis Looks Forward In Ovarian Cancer 
Chart BRISTOL-MYERS SQUIBB COMPANY
Duration : Period :
Bristol-Myers Squibb Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQUIBB COMPA
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 59,4 $
Spread / Average Target -2,7%
EPS Revisions
Managers
NameTitle
Giovanni Caforio Chairman & Chief Executive Officer
Charles A. Bancroft CFO, EVP & Head-Global Business Operations
Paul von Autenried Chief Information Officer & Senior Vice President
Thomas James Lynch Chief Scientific Officer & Executive VP
Vicki L. Sato Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB COMPANY-0.28%97 847
JOHNSON & JOHNSON-5.18%347 417
PFIZER14.36%238 136
NOVARTIS-0.83%207 488
ROCHE HOLDING LTD.-2.96%206 696
MERCK AND COMPANY22.36%176 752